Srivastava Rajnish, Dilnashin Hagera, Kapoor Devesh, Aparna Sai, Heidarli Elmira, Singh Surya Pratap, Jain Vivek
Moradabad Educational Trust Group of Institutions, Faculty of Pharmacy, Moradabad 244001, Uttar Pradesh, India.
Department of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi 221005, Uttar Pradesh, India.
CNS Neurol Disord Drug Targets. 2024;23(2):181-202. doi: 10.2174/1871527322666230223150347.
Animal models for drug discovery and development in Parkinson 's disease have played an important role in the characterization of the pathophysiology of diseases and associated mechanisms of injury, drug target identification, and evaluation of novel therapeutic agents for toxicity/ safety, pharmacokinetics, pharmacodynamics, and efficacy.
The review is intended to reform the scope, advantages, and limitations of various Parkinson's Disease models and their scope in translational research. The lack of a gold standard for PD animal models presents a major challenge in devising a validation system. This review is an attempt to provide a way to adopt the validation approach for PD animal model for research.
Because underlying disease mechanisms are so similar across species, it is possible to extrapolate results from Parkinson's disease studies using animal models. Furthermore, behavioural tests used to access the neurobehavioral test with its limitations were explored for rodents, non-human primates, lower-order animals, and invertebrates. The role of gender selectivity and non-selectivity is the one major concern in PD model validation that is addressed in the review.
The rigorous validation has been done on animal models for Parkinson's disease (PD) based on comparisons to the human state. Regarding toxicological and safety investigations in PD, non-animal options must be thoroughly validated. There are both advantages and disadvantages to using animal models of Parkinson's disease as proof-of-concept research.
The specific animal model selected for a given drug to be tested and developed depends on the goal of the specific study.
帕金森病药物研发的动物模型在疾病病理生理学特征及相关损伤机制的研究、药物靶点识别以及新型治疗药物的毒性/安全性、药代动力学、药效学和疗效评估中发挥了重要作用。
本综述旨在探讨各种帕金森病模型的范围、优势和局限性及其在转化研究中的应用范围。帕金森病动物模型缺乏金标准给验证系统的设计带来了重大挑战。本综述旨在尝试提供一种采用帕金森病动物模型验证方法进行研究的途径。
由于不同物种的潜在疾病机制非常相似，因此有可能从帕金森病动物模型研究中推断出结果。此外，还探讨了用于评估啮齿动物、非人灵长类动物、低等动物和无脊椎动物神经行为测试及其局限性的行为测试。性别选择性和非选择性的作用是帕金森病模型验证中的一个主要问题，本综述对此进行了探讨。
基于与人类状态的比较，已对帕金森病（PD）动物模型进行了严格验证。在帕金森病的毒理学和安全性研究方面，必须对非动物选项进行全面验证。将帕金森病动物模型用作概念验证研究既有优点也有缺点。
为特定待测试和研发药物选择的具体动物模型取决于特定研究的目标。
